Search results for "L. Bueno. Mechanisms involved in bacterial pathogen-induced intestinal mucosal barrier disruption: Therapeutic interest of mecha"

Presented at GFHGHP 2012. Presented as oral communication at the 33rd edition of the Congress from the Groupe Francophone d'Hépato-Gastroentérologie et Nutrition Pédiatriques in Nantes, France, March 2012. Abstract: New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 1: filmforming effect. Freli V, Moreira da Silva R, Pescio P
Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715.
Let’s celebrate 2022 with a new paper on Utipro® Plus and Utipro® Plus AF!! We are pleased to announce the publication of a meta-analysis in which the benefit of the combination of a mucoprotectant (xyloglucan or an equivalent substance), hibiscus and propolis in the management of uncomplicated urinary tract infections has been evaluated.
Efficacy of gelatin tannate for acute diarrhea in children: a systematic review and meta-analysis. AIM: To investigate by meta-analysis the efficacy of gelatin tannate (GT), a mucosal barrier protector, in children with acute gastroenteritis.
·       EPA3G a unique, patented emulsion of high purity EPA, in drinkable single sachet - containing daily dose of 3g ·       Deal gives Noventure licensing rights in over 50 countries ·       Agreement signed with global partner Azur Global Nutrition
Abstracts / Digestive and Liver Disease 45 (2013) e263–e311 Background and aims:
Eur Rev Med Pharmacol Sci . 2017; 21 (4): 873-883 Objective:
Rodriguez-Mañas L. Urinary tract infections in the elderly: a review of disease characteristics and current treatment options. Drugs in Context 2020; 9: 2020-4-13. DOI: 10.7573/dic.2020-4-13. Free PMC article. Abstract:
Allergy Asthma Clin Immunol. 2017 Aug 10;13:37  Full text free!! Abstract: Background: To evaluate barrier protective properties of Rhinosectan® spray, a medical device containing xyloglucan, on nasal epithelial cells (MucilAir).